Jun. 27 at 3:57 AM
$MDAI I don't post often, but I've seen people confused about the price action over the last couple of weeks and I wanted to try and shed some light on both biotech as a whole and MDAI and their business plan with the DeepView deployment.
First of all, I'm no expert, but I was in both ARDX and CHRS under
$1. ARDX was a very similar situation MDAI finds itself in now. Waited for approval for their flagship, PA raising the entire way, only to fall off a cliff when the news came out that they received it. This story isn't unique to MDAI, and it's a very common exit point for many long term holders. Sure enough, randomly about 6 months after ADCOM, ARDX rose to meet and then exceed the median PTs. Not a single sale yet, and no news.
The point I'm trying to make is that if you're long, it's better to focus on analyzing the business and not the price action at this stage.
PT.1
